Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raed Al-Rajabi

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Current Opinion in Gastroenterology|January 28, 2021
Immunotherapy in cholangiocarcinomaRaed Al-Rajabi, Weijing Sun
Clinical Colorectal Cancer|March 26, 2019
Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced CholangiocarcinomaAnwaar Saeed, Robin Park, Mohammed Al-Jumayli, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 3, 2020
Controversies in Rectal Cancer Treatment and ManagementWeijing Sun, Raed Al-Rajabi, Rodrigo O Perez, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 8, 2023
A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicityAnup Kasi, Pramod Gaudel, Manidhar Lekkala, et al.
JAMA Network Open|December 16, 2020
Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysisAnup Kasi, Saqib Abbasi, Shivani Handa, et al.
Journal of Clinical Medicine|October 17, 2020
Association of Neutrophil, Platelet, and Lymphocyte Ratios with the Prognosis in Unresectable and Metastatic Pancreatic CancerJessica Allen, Colin Cernik, Suhaib Bajwa, et al.
Journal of Gastrointestinal Oncology|June 2, 2015
Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunctionRaed Al-Rajabi, Sukeshi Patel, Norma S Ketchum, et al.
BMC Cancer|June 5, 2020
Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic reviewGhulam Rehman Mohyuddin, Muhammad Aziz, Alec Britt, et al.
Journal of Oncology|June 13, 2019
Clinical Outcome of Ampullary Carcinoma: Single Cancer Center ExperienceMohammed Al-Jumayli, Amna Batool, Akshay Middiniti, et al.
Journal of Clinical Medicine|August 23, 2020
Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective StudyAnwaar Saeed, Hannah Hildebrand, Robin Park, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Current Opinion in Gastroenterology|January 28, 2021
Immunotherapy in cholangiocarcinomaRaed Al-Rajabi, Weijing Sun
Clinical Colorectal Cancer|March 26, 2019
Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced CholangiocarcinomaAnwaar Saeed, Robin Park, Mohammed Al-Jumayli, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 3, 2020
Controversies in Rectal Cancer Treatment and ManagementWeijing Sun, Raed Al-Rajabi, Rodrigo O Perez, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 8, 2023
A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicityAnup Kasi, Pramod Gaudel, Manidhar Lekkala, et al.
JAMA Network Open|December 16, 2020
Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysisAnup Kasi, Saqib Abbasi, Shivani Handa, et al.
Journal of Clinical Medicine|October 17, 2020
Association of Neutrophil, Platelet, and Lymphocyte Ratios with the Prognosis in Unresectable and Metastatic Pancreatic CancerJessica Allen, Colin Cernik, Suhaib Bajwa, et al.
Journal of Gastrointestinal Oncology|June 2, 2015
Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunctionRaed Al-Rajabi, Sukeshi Patel, Norma S Ketchum, et al.
BMC Cancer|June 5, 2020
Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic reviewGhulam Rehman Mohyuddin, Muhammad Aziz, Alec Britt, et al.
Journal of Oncology|June 13, 2019
Clinical Outcome of Ampullary Carcinoma: Single Cancer Center ExperienceMohammed Al-Jumayli, Amna Batool, Akshay Middiniti, et al.
Journal of Clinical Medicine|August 23, 2020
Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective StudyAnwaar Saeed, Hannah Hildebrand, Robin Park, et al.
Pageof 3